Pfizer, Novo Nordisk Locked in High-Stakes Fight Over Obesity Drug Innovator Metsera
NeutralArtificial Intelligence
Pfizer, Novo Nordisk Locked in High-Stakes Fight Over Obesity Drug Innovator Metsera
Pfizer and Novo Nordisk are currently engaged in a competitive struggle to acquire Metsera, a developer of obesity drugs. This battle is significant as it highlights the growing market for obesity treatments and the lengths major pharmaceutical companies will go to secure innovative solutions. The outcome could reshape the landscape of obesity management and influence future drug development.
— via World Pulse Now AI Editorial System
